EXPLORING NRF2 AS A NOVEL THERAPEUTIC TARGET IN SICKLE CELL DISEASE

被引：0
|
作者：
Owusu-Ansah, Amma [1 ]
Meyerson, Howard [1 ]
Letterio, John [1 ]
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
来源：
PEDIATRIC BLOOD & CANCER | 2012年 / 58卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1025 / 1026
页数：2
相关论文
共 50 条
  • [21] Nrf2 is a new therapeutic target to slow progression of Parkinson's disease
    Cuadrado, A.
    JOURNAL OF NEUROCHEMISTRY, 2013, 125 : 85 - 85
  • [22] Transcription factor NRF2 as a promising therapeutic target for Alzheimer's disease
    Qu, Zhuo
    Sun, Jiachen
    Zhang, Wannian
    Yu, Jianqiang
    Zhuang, Chunlin
    FREE RADICAL BIOLOGY AND MEDICINE, 2020, 159 : 87 - 102
  • [23] The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease
    Cuadrado, Antonio
    Moreno-Murciano, Paz
    Pedraza-Chaverri, Jose
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (03) : 319 - 329
  • [24] Nrf2 as a novel molecular target for chemoprevention
    Lee, JS
    Surh, YJ
    CANCER LETTERS, 2005, 224 (02) : 171 - 184
  • [25] Role of NRF2 as a Therapeutic Target for RGC Protection
    Li, Qiutang
    Liu, Ting
    Rong, Yu
    Zhang, Xin
    Luk, Alvin
    Li, Bin
    MOLECULAR THERAPY, 2022, 30 (04) : 143 - 143
  • [26] Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases
    Nakagami, Yasuhiro
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2016, 2016
  • [27] Nrf2 as an emerging therapeutic target in metastatic melanoma
    Hobson, Emily
    Cowan, Jonathan
    O'Connell, Maria
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 (04) : 493 - 494
  • [28] Nrf2 activation as target to implement therapeutic treatments
    Bocci, Velio
    Valacchi, Giuseppe
    FRONTIERS IN CHEMISTRY, 2015, 3
  • [29] Nrf2: a potential therapeutic target for diabetic neuropathy
    Anil Kumar
    Ruchika Mittal
    Inflammopharmacology, 2017, 25 : 393 - 402
  • [30] Nrf2: a potential therapeutic target for diabetic neuropathy
    Kumar, Anil
    Mittal, Ruchika
    INFLAMMOPHARMACOLOGY, 2017, 25 (04) : 393 - 402
12345